Zealand Pharma — November 2022

[exitnu]

Announced positive topline results from the pivotal Phase 3 EASE-1 trial of glepaglutide, a long-acting GLP-2 analogue designed for subcutaneous delivery via auto-injector, in patients with short bowel syndrome (SBS).

[exitnu]

Reported results from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906, a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in patients with type 2 diabetes (T2D) at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD).

[exitnu]

Presented results from the Phase 3 clinical trial of dasiglucagon in congenital hyperinsulinism (CHI) at the 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE).

[exitnu]

Completed dose escalation in the ongoing Phase 1a single ascending dose (SAD) trial of ZP8396, a long-acting amylin analogue.

[exitnu]

Announced a global license and development agreement with Novo Nordisk to commercialize ZEGALOGUE (dasiglucagon) for injection.

[exitnu]

Personligt synes jeg at Zealand Pharma har overpræsteret. Alt går deres/vores vej ...

[exitnu]

@Pensionisten - gider du venligst uddybe - tak!

[exitnu]

Plus disse fire begivenheder:

Presented preclinical data at the Annual Meeting of the Obesity Society (Obesity Week). Reported results from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906 (GCGR/GLP-1R) in patients with T2D at Obesity Week. Phase 2 trial of BI 456906 in patients with non-alcoholic steatohepatitis (NASH). Received gross proceeds of DKK 786 million from a directed issue and private placement.

[ProinvestorNEWS]

[Svingtraderen]

morning i klubben:)

[Svingtraderen]

22:21 synes det er væltet ind med nyheder i min Q3 - aktien er steget fra 75 til 190. Er op ca 30% i år mens markedet er ned 20%. Kan ikke liiige se hvad der mangler:)

[Svingtraderen]

og tak @exitnu

[exitnu]

ILM

[Helge_LarsenPI-redaktør]

Spørgsmål til Q&A er meget velkommen. Jo før jo bedre.

[Munchi]

hvad sker der her til morgen ? 179

[Svingtraderen]

samme spørgsmål

[Munchi]

almindelig skuffelse over non event ?

[deleted-user]

Der mangler indtægter i regnskabet, det burde ikke overrasket markedet synderligt. Men kurser har nok været lidt for optimistisk de seneste uger

[Svingtraderen]

ligner nogen har nedjusteret anbefaling/target

[deleted-user]

De gode nyheder har stået i kø og flyttet fokus fra, at selskabet forsat er ren udvikling med begrænset "forretning" trods alt. Spændende tid vi går i møde, men slaget er ikke overstået de kommende 1-2-3 måneder. Det tager tid, som en god ost.